|
An Industry Panel and Networking Reception
Thursday, September 23, 2010
Agenda
3:00 PM - 3:30 PM Registration and Networking
3:30 PM - 5:00 PM Industry Panel
5:00 PM - 6:30 PM Networking Reception
From alliance to funding, Big Pharma and established biotech companies are increasingly investing in emerging companies. This Panel brings together executives from these larger companies to identify the type of deals now available to smaller companies, how to secure them, and how to manage them.
Questions that will be raised include:
• What are the best approaches for identifying a good partner?
• What type of partnerships are commonly used? And is your company a best candidate for a simple license, or a full blown joint venture, or a M&A?
• What about the rising of Big Pharma VC Funds?
• What are the strategies for attracting, securing and structuring strategic investments?
• How the Larger Bio-Companies’ needs differ from VCs’ needs?
• What are the key contract terms to be negotiated?
• What are the strategic reasoning behind different kinds partnerships?
• Effects on existing and potential future collaboration partners and other strategic decisions.
• Pros and cons of a small company partnering with a larger company.
• “Dos” and “don’ts” of managing these important relationships.
Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.
Venue
Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Building 1100
Menlo Park, CA 94025-1015
Click here for Venue Directions»
Speakers Bios
Dr. Yael Weiss, Director of Licensing & External Research, Merck Research Laboratories, Merck & Co., Inc.
Yael completed her MSc and PhD in molecular genetics at the Weizmann Institute of Science, Rehovot, Israel and obtained her medical degree at Hadassah Medical Center, affiliated with The Hebrew University of Jerusalem, Israel. After practicing medicine for a few years, Yael joined an Israeli venture capital firm as a vice president responsible for analyzing and maintaining deal flow, and then moved on to become a medical and business development director at Genzyme Israel. Yael joined MSD Israel as medical director in the beginning of 2004 and in 2007 she joined Merck's Licensing group in San Francisco as a scientific scout responsible for identification of licensing opportunities emanating from the West Coast.
|